Short Interest in Black Titan Corp (NASDAQ:BTTC) Declines By 44.3%

Black Titan Corp (NASDAQ:BTTC) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totaling 2,400 shares, a decrease of 44.3% from the May 31st total of 4,312 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 88,396 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Black Titan

Several institutional investors and hedge funds have recently made changes to their positions in BTTC. Renaissance Technologies LLC bought a new position in Black Titan during the 4th quarter worth about $26,000. HRT Financial LP purchased a new stake in shares of Black Titan in the 4th quarter worth approximately $28,000. Marex Group plc bought a new position in shares of Black Titan during the fourth quarter valued at approximately $84,000. Finally, Armistice Capital LLC bought a new position in shares of Black Titan during the fourth quarter valued at approximately $840,000.

Black Titan Trading Up 0.5%

Shares of NASDAQ BTTC traded up $0.00 during trading hours on Thursday, reaching $0.76. The stock had a trading volume of 10,200 shares, compared to its average volume of 739,493. The company has a current ratio of 4.62, a quick ratio of 4.62 and a debt-to-equity ratio of 0.06. The firm has a market cap of $8.15 million, a price-to-earnings ratio of -0.26 and a beta of 1.21. The company has a fifty day moving average price of $1.05. Black Titan has a 52-week low of $0.68 and a 52-week high of $39.00.

Black Titan (NASDAQ:BTTC) last released its quarterly earnings data on Friday, June 12th. The company reported ($0.22) EPS for the quarter. The business had revenue of $0.59 million during the quarter.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.